For years, experts have debated the evolving value proposition of higher education. But what do students think about it? To find out, The Chronicle partnered with Langer Research Associates to ...

FROM land rows to family feuds, Justice Minister Delroy Chuck says unresolved community conflicts are feeding the nation’s ...

Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a detailed analysis.

If you’re at all concerned about privacy, the rise of AI personal assistants can feel alarming. It’s difficult to use one without sharing personal information, which is retained by the model’s parent ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

The Food and Drug Administration plans to select about 40 devices not yet cleared by the agency to receive special agency discretion to participate in the new chronic care Advancing Chronic Care with ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

In 2018, the California state legislature set the goal of reaching net-zero carbon emissions by 2045 in the California Climate Crisis Act. In September of 2025, a team of Stanford researchers ...

With health care cuts an ongoing concern for people across the U.S., here’s what should concern New Yorkers the most: the health care workforce shortage, with unfilled positions straining services ...

Our body's "blood factory" consists of specialized tissue made up of bone cells, blood vessels, nerves and other cell types. Now, researchers have succeeded for the first time in recreating this ...